Long‐Term Opioid Therapy and Risk of Opioid Overdose by Derived Clinical Indication in North Carolina, 2006–2018
Pharmacoepidemiology and Drug Safety · 2025
DOI: 10.1002/pds.70090 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2025. Verfasst von Bethany L DiPrete und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, USA. Hauptthemen laut MEDLINE: Analgesics, Opioid, Opiate Overdose, Drug Overdose. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Purpose
Long‐term opioid therapy (LTOT) has been shown to be associated with opioid overdose, but the definition of LTOT varies widely across studies. We use a rigorous LTOT definition to examine risk of opioid overdose by duration of treatment.
Methods
Data were from a large private health insurance provider in North Carolina linked to mortality records from 2006–2018. Eligible patients were adults (18–64) newly initiating opioid therapy after a pain diagnosis or surgery. We defined LTOT as ≥ 1 opioid prescription per month totaling ≥ 60 days' supply within 90 days. We used inverse probability (IP)‐weighted cumulative incidence functions to estimate three‐year risk of opioid overdose and IP‐weighted Fine–Gray models to estimate sub‐distribution hazard ratios, comparing LTOT to short‐ to medium‐term opioid therapy (SMTOT). We also examined modification by derived indication of acute pain or surgery versus chronic pain.
Results
We identified 491 369 patients, and 1.7% were exposed to LTOT. The three‐year risk of opioid overdose was 0.3 percentage points (RD w = 0.003, 95% CI: 0.001, 0.005) higher in LTOT patients compared to patients with SMTOT. The weighted hazard of opioid overdose was 4.4 times as high (HR w 4.42, 95% CI 2.41, 8.11) among patients exposed to LTOT versus SMTOT. We did not find meaningful modification by clinical indication for opioid therapy.
Conclusions
Exposure to LTOT was associated with increased risk of opioid overdose in this population of privately insured patients using a rigorous definition of LTOT. These findings confirm the importance of guidelines to minimize duration of opioid therapy whenever possible.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, USA.
- Injury Prevention Research Center, University of North Carolina, Chapel Hill, USA.
- Carolina Population Center, University of North Carolina, North, USA.
- Department of Geography, University of North Carolina, North, USA.
ORCID-Profile: Bethany L DiPrete, Shabbar I Ranapurwala
Förderung
- NCATS NIH HHS
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
- NCIPC CDC HHS
- NIDA NIH HHS
- CDC HHS
- National Institute on Drug Abuse
- Centers for Disease Control and Prevention
Zitieren
APA
DiPrete, B. L., Ranapurwala, S. I., Pettifor, A. E., Powers, K. A., Delamater, P. L., Fulcher, N., & Pence, B. W. (2025). Long‐Term Opioid Therapy and Risk of Opioid Overdose by Derived Clinical Indication in North Carolina, 2006–2018. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70090
Vancouver
DiPrete BL, Ranapurwala SI, Pettifor AE, Powers KA, Delamater PL, Fulcher N, et al. Long‐Term Opioid Therapy and Risk of Opioid Overdose by Derived Clinical Indication in North Carolina, 2006–2018. Pharmacoepidemiology and Drug Safety. 2025. doi:10.1002/pds.70090
BibTeX
@article{DiPrete2025,
author = {DiPrete, Bethany L and Ranapurwala, Shabbar I and Pettifor, Audrey E and Powers, Kimberly A and Delamater, Paul L and Fulcher, Naoko and Pence, Brian W},
title = {Long‐Term Opioid Therapy and Risk of Opioid Overdose by Derived Clinical Indication in North Carolina, 2006–2018},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2025},
doi = {10.1002/pds.70090}
}
EUVIMED